It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Epstein-Barr virus (EBV) immortalization of resting B lymphocytes (RBLs) to lymphoblastoid cell lines (LCLs) models human DNA tumor virus oncogenesis. RBL and LCL chromatin interaction maps are compared to identify the spatial and temporal genome architectural changes during EBV B cell transformation. EBV induces global genome reorganization where contact domains frequently merge or subdivide during transformation. Repressed B compartments in RBLs frequently switch to active A compartments in LCLs. LCLs gain 40% new contact domain boundaries. Newly gained LCL boundaries have strong CTCF binding at their borders while in RBLs, the same sites have much less CTCF binding. Some LCL CTCF sites also have EBV nuclear antigen (EBNA) leader protein EBNALP binding. LCLs have more local interactions than RBLs at LCL dependency factors and super-enhancer targets. RNA Pol II HiChIP and FISH of RBL and LCL further validate the Hi-C results. EBNA3A inactivation globally alters LCL genome interactions. EBNA3A inactivation reduces CTCF and RAD21 DNA binding. EBNA3C inactivation rewires the looping at the CDKN2A/B and AICDA loci. Disruption of a CTCF site at AICDA locus increases AICDA expression. These data suggest that EBV controls lymphocyte growth by globally reorganizing host genome architecture to facilitate the expression of key oncogenes.
The dynamic and temporal changes of host genome architecture during Epstein-Barr virus (EBV) transformation are not well known. Here the authors transform human primary B lymphocyte into lymphoblastoid cell lines (LCLs) with EBV and show that the host 3D genome is rewired to facilitate expression of key oncogenes.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details










1 Brigham and Women’s Hospital and Harvard Medical School, Division of Infectious Disease, Department of Medicine, Boston, USA (GRID:grid.62560.37) (ISNI:0000 0004 0378 8294); University of Minnesota, Department of Diagnostic and Biological Sciences, School of Dentistry, Minneapolis, USA (GRID:grid.17635.36) (ISNI:0000000419368657)
2 H. Lee Moffitt Cancer Center and Research Institute, Department of Biostatistics and Bioinformatics, Tampa, USA (GRID:grid.468198.a) (ISNI:0000 0000 9891 5233)
3 Brigham and Women’s Hospital and Harvard Medical School, Division of Infectious Disease, Department of Medicine, Boston, USA (GRID:grid.62560.37) (ISNI:0000 0004 0378 8294)
4 Brigham and Women’s Hospital and Harvard Medical School, Division of Infectious Disease, Department of Medicine, Boston, USA (GRID:grid.62560.37) (ISNI:0000 0004 0378 8294); H. Lee Moffitt Cancer Center and Research Institute, Department of Cancer Physiology, Tampa, USA (GRID:grid.468198.a) (ISNI:0000 0000 9891 5233)
5 Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Guangzhou, China (GRID:grid.488530.2) (ISNI:0000 0004 1803 6191)
6 Sun Yat-sen University, Zhongshan School of Medicine, Guangzhou, China (GRID:grid.12981.33) (ISNI:0000 0001 2360 039X)
7 Cincinnati Children’s Hospital Medical Center, Center for Autoimmune Genomics and Etiology, Cincinnati, USA (GRID:grid.239573.9) (ISNI:0000 0000 9025 8099)
8 Beth Israel Deaconess Medical Center and Harvard Medical School, Center for Virology and Vaccine Research, Boston, USA (GRID:grid.239395.7) (ISNI:0000 0000 9011 8547)